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Abstract
Dysbiosis of the gut microbiome and related metabolites in chronic kidney disease (CKD) have been intimately associated 
with the prevalence of cardiovascular diseases. Unfortunately, thus far, there is a paucity of sufficient knowledge of gut 
microbiome and related metabolites on CKD progression partly due to the severely limited investigations. Using a 5/6 
nephrectomized (NX) rat model, we carried out 16S rRNA sequence and untargeted metabolomic analyses to explore the 
relationship between colon’s microbiota and serum metabolites. Marked decline in microbial diversity and richness was 
accompanied by significant changes in 291 serum metabolites, which were mediated by altered enzymatic activities and 
dysregulations of lipids, amino acids, bile acids and polyamines metabolisms. Interestingly, CCr was directly associated 
with some microbial genera and polyamine metabolism. However, SBP was directly related to certain microbial genera and 
glycine-conjugated metabolites in CKD rats. Administration of poricoic acid A (PAA) and Poria cocos (PC) ameliorated 
microbial dysbiosis as well as attenuated hypertension and renal fibrosis. In addition, treatments with PAA and PC lowered 
serum levels of microbial-derived products including glycine-conjugated compounds and polyamine metabolites. Collec-
tively, the present study confirmed the CKD-associated gut microbial dysbiosis and identified a novel dietary and therapeutic 
strategy to improve the gut microbial dysbiosis and the associated metabolomic disorders and retarded the progression of 
kidney disease in the rat model of CKD.
Keywords Renal fibrosis · Gut microbiota · Metabolome · Hypertension · Creatinine clearance rate · Polyamine metabolism
Introduction
Chronic kidney disease (CKD) has emerged as a major pub-
lic health problem with increased morbidity and mortality. 
Patients with CKD are at increased risk for the develop-
ment of cardiovascular disease (CVD) beyond traditional 
risk factors [1]. Angiotensin-converting enzyme inhibitors 
and angiotensin receptor blockers are identified as the first-
line therapies that proved efficient to retard the progression 
of hypertension, CVD and CKD [2]. Nevertheless, although 
this approach is undoubtedly effective, many CKD patients 
who are treated with these drugs progress to end-stage renal 
disease (ESRD), underscoring the importance of novel ther-
apeuties on disease intervention.
The human gut is heavily populated with myriad microor-
ganisms. The normal gut microbial community forms a natu-
ral defense barrier and favorably influences the hosts’ physi-
ology, immune function, nutrition, inflammatory signaling 
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and metabolisms of lipids, bile acids, indole, choline, short-
chain fatty acids, etc. [3, 4]. Among them, the levels of low-
molecular-weight metabolites are closely associated with 
the composition of the gut microbiota. Metabolites derived 
from the gut’s bacteria provide an insight into the metabolic 
state of an individual [5]. Various clinical and animal stud-
ies have demonstrated the critical role of the gut microbiota 
in both health maintenance and disease pathogenesis [3, 
4]. Under normal conditions, there is equilibrium between 
the intestinal bacteria and the host, via the innate immunity 
that maintains the balance of inflammation and intestinal 
barrier integrity. However, by altering the biochemical and 
biophysical milieu of the intestinal tract, advanced CKD 
results in intestinal epithelial barrier disruption and micro-
bial dysbiosis [6]. Recent studies have illuminated the effect 
of CKD on the gut microbiota pointing to the kidney–gut 
axis [7]. CKD has been shown to result in the dysbiosis of 
the gut microbiota, leading to an increased production of 
various uremic toxins including indoxyl sulfate (IS), p-cresyl 
sulfate (p-CS), trimethylamine and trimethylamine N-oxide 
(TMAO) [7] which accelerate the progression of CKD to 
ESRD by intensifying inflammation [8].
A deeper understanding of the gut microbiome–metabo-
lome axis is a prerequisite to improve therapeutic strategies 
that manipulate the gut microbiota in the course of develop-
ment of CKD. It has been reported that patients with ESRD 
have expansion of Firmicutes, Actinobacteria and Proteo-
bacteria phyla and reduction of Bifidobacteria and Lactoba-
cilli populations in their colons [9]. Several studies have also 
uncovered marked alteration of the microbiota composition 
in hemodialysis patients [10]. Alterations in microbiome 
composition results in increased generation of lipopolysac-
charide, IS, p-CS, amines and ammonia that lead to the acti-
vation of proinflammatory cytokine/chemokine cascades in 
CKD and ESRD [11]. Elevation of IS and p-PC levels may 
accelerate the progression of CKD and the CKD-associated 
cardiovascular diseases [12]. In fact, a series of clinical stud-
ies have demonstrated the association of increased IS and 
p-CS levels with the progression and mortality of renal dis-
eases in CKD/ESRD populations [8]. Moreover, elevated IS 
and p-CS levels were implicated in high levels of inflamma-
tory markers in patients with CKD and played pivotal roles 
in the prediction of CKD progression [13]. The relationship 
between fasting serum TMAO and all-cause mortality over 
a 5-year follow-up were examined in 521 subjects with sta-
ble CKD. Serum TMAO levels were significantly increased, 
which was closely involved in poor long-term survival in 
CKD patients and progressive renal fibrosis in CKD animals 
[14].
Heretofore, few studies have been assigned to explore 
the direct association between gut microbiome and serum 
metabolites in CKD [8]. Several important gaps in knowl-
edge of gut microbiota and endogenous metabolites remain 
unexplored and deeper investigations are urgently needed. 
To this end, we first applied 16S rDNA sequencing tech-
nique and untargeted metabolomics to determine the effect 
of CKD on the gut microbiome and serum metabolites in 
rats with CKD induced by 5/6 nephrectomy (NX). In addi-
tion, an independent experiment was performed to verify 
the identified microbiota and metabolites as well as discover 
new intervention strategy on gut microbiota, hypertension 
and renal fibrosis in CKD.
Materials and methods
Experimental animals
Male Sprague–Dawley rats (180–200 g) were purchased 
from the Central Animal Breeding House of Xi’an Jiaotong 
University (Xi’an, Shaanxi, China). Animal protocols were 
approved by Northwest University institutional animal care 
and use committee (Permit Number: SYXK 2010-004). The 
rats (n = 12) were randomized into two groups: sham and NX 
groups. The NX were performed as previously described 
[15]. Briefly, the 2/3 of the left kidney and the whole right 
kidney were removed by scalpel excision. Gelfoam coag-
ulant was further applied on the cut surfaces. The Sham 
were merely subjected to laparotomy. To verify the iden-
tified microbiota and metabolites as well as discover new 
intervention strategy, a separate experiment was performed. 
CKD rats were treated with Poria cocos (PC, a well-known 
medicinal compound derived from fungal mushroom) and 
poricoic acid A (PAA, a tetracyclic triterpenoid compound 
isolated from PC) or placebo. They were randomized 
into four groups (n = 8/group): sham, NX, NX + PAA and 
NX + PC. The ethanol-extracted PC (250 mg/kg/day) and 
PAA (10 mg/kg/day) were gavaged into NX rats. All ani-
mals were provided access to water and food ad libitum. 
The sham-operated, NX and treated rats were sacrificed at 
week 12. Blood, colonic luminal contents, colon tissues and 
kidney tissues were collected and processed for 16S rRNA 
sequence, untargeted and targeted metabolomic, histological 
and western blot analyses.
Renal function and blood pressure
Serum creatinine, urea and proteinuria were measured by 
Olympus AU6402 automatic analyzer. Additionally, creati-
nine clearance rate (CCr) was calculated on the basis of rel-
evant data and a weekly measurement of blood pressure was 
performed by rat tail plethysmograph as well(Techman Soft, 
Chengdu, China).
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Histological analysis
Glomerulosclerosis and tubulointerstitial damage were 
assessed by periodic acid–Schiff (PAS) staining and Mas-
son’s trichrome staining as previously described [16]. Immu-
nohistochemistry (IHC) procedure was carried out as pre-
viously described [17]. The histological assessments were 
performed by two independent pathologists. After immu-
nohistochemical analysis, Image-Pro plus software version 
6.0 was used to analyze the optical density of the images as 
described previously [17, 18].
Western blot analyses
The primary antibodies including ZO1, occludin, claudin-1, 
IκBα, p-IκBα, NF-κB p65, monocyte chemotactic protein-1 
(MCP-1), cyclooxygenase-2 (COX-2), Keap1, Nrf2, heme 
oxygenase 1 (HO-1), catalase, NAD(P)H quinone dehydro-
genase 1 (NQO1), α smooth muscle actin (α-SMA), collagen 
I and fibronectin were purchased from Abcam and Santa 
Cruz Companies. Colon and kidney tissues were processed 
for western blot analyses as previously described [19, 20]. 
Blots were processed with ECL reagent and protein con-
centrations were normalized against α-tubulin expression.
High‑throughput sequencing of colon lumen DNA
The colon lumen of each sample was stored at − 80 °C 
for DNA extraction and dissected with sterilized blade. 
Genomic DNA was extracted using a E.Z.N.A.® Soil DNA 
Kit (Omega Bio-tek, Norcross, GA, USA) according to man-
ufacturer’s protocols. The concentrations and purity of the 
resultant DNA were determined by a NanoDrop (NanoDrop 
ND-2000, USA), which was stored at − 80 °C for further 
analysis.
The 16S rRNA gene was amplified by PCR with primers 
16s-F (5′-AGA GTT TGATYMTGG CTC AG-3′) and 16s-R 
(5′-TGC TGC CTC CCG TAG GAG T-3′) targeting the hyper-
variable V4–V5 region of the 16S rRNA gene of bacteria. 
PCR reactions were performed in triplicates with  Phusion® 
High-Fidelity PCR Master Mix (New England Biolabs) 
using 10 ng template DNA. PCR products were purified 
using the AxyPrep DNA Gel Extraction Kit (Axygen Bio-
sciences, Union City, CA, USA) according to the manufac-
turer’s instructions and quantified using QuantiFluor™-ST 
(Promega, USA). The PCR products of different samples 
were mixed equally and subsequently used to construct Illu-
mina Pair-End library using  Next® Ultra™ DNA Library 
Prep Kit for Illumina (NEB, USA). Then, the amplicon 
library was paired end sequenced (2 × 250) on an Illumina 
HiSeq 2500 platform (Illumina, SanDiego, USA) according 
to the standard protocols.
Processing of 16S rRNA gene sequences
Raw fastq files were demultiplexed using the barcode 
sequence with the exact barcode matching parameter. Qual-
ity filtering was done using Trimmomatic (version 0.36) 
[21] with the following criteria: (1) bases off the start and 
end of a read below a threshold quality (score < 3) were 
removed, (2) the reads were truncated at any site receiving 
an average quality score < 5 over a 4-bp sliding window, 
discarding the truncated reads that were shorter than 100 bp. 
Paired reads were merged using USEARCH fastq_merge 
pairs command (version 9.2.64, http://drive 5.com/upars e/) 
[22] with the default parameters. Operational units (OTUs) 
were clustered with 97% similarity cutoff using USEARCH 
UPARSE [23]. The chimeric sequences were removed in 
the UPARSE pipeline. The phylogenetic affiliation of each 
16S rRNA gene sequence was analyzed by USEARCH SIN-
TAX algorithm [24] against the RDP training set (version 
v16) 16S rRNA database using confidence threshold of 0.8. 
The OTUs identified as mitochondrial or chloroplast rRNA 
sequences were discarded. The rarefaction analysis based 
on USEARCH α_divisity [25] was conducted to reveal the 
diversity indices, including the richness, chao1, Simpson 
and Shannon diversity indices. The β diversity analysis was 
performed using UniFrac metrics [26] in QIIME (version 
1.9.1) [27] pipeline.
Sample preparation and UPLC–MS analysis 
for metabolomics
Serum metabolites were performed using an untargeted 
metabolomics UPLC–HDMS. The metabolomic proce-
dure, including sample preparation, metabolite separation 
and detection, data preprocessing and statistical analysis for 
metabolite identification, was performed following our pre-
vious protocols with minor modifications [28–31].
Statistics analysis
The statistical analyses were performed using R 2.15.0 
and GraphPad Prism software v 5.0. PCA and OPLS-DA 
were performed using SIMCA-P software to cluster the 
sample plots across groups. All the data were presented as 
mean ± SEM. The significance of the difference between 
two groups was analyzed using Student’s unpaired t test, 
and multiple comparisons were analyzed using one-way 
ANOVA followed by Dunnett’s post hoc test. Differential 
abundances of genera and metabolites were determined by 
non-parametric tests including Wilcoxon rank sum test and 
Mann–Whitney U test. Serum metabolite intensities were 
then tested for association with 16S levels using Spear-
man rank correlation. P values were corrected for multiple 
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comparisons using the Benjamini–Hochberg false discovery 
rate (FDR) and P < 0.05 was statistically significant.
Results
General data
Compared to sham rats, the CKD rats showed marked 
increase in urine output, systolic blood pressure (SBP), 
diastolic blood pressure (DBP), serum creatinine, urea and 
proteinuria, while body weight, creatinine clearance (CCr) 
and hematocrit were evidently decreased (Fig. 1a).
The gut microbiome data
Gut microbiome was determined by Illumina Miseq 
sequencing using specimen colonic luminal content sam-
ples of NX and sham rats. A total of 802 OTUs, with an 
average of 553 OTUs per sample, were identified from 
254,147 quality-filtered sequences in the CKD and sham 
groups. The α-diversity indexes including Chao1, Shannon 
and Simpson were used to determine the ecological diversity 
within microbial community. The Shannon index reflecting 
both the species richness and evenness was 6.74 ± 0.25 and 
6.89 ± 0.19 in sham and CKD rats, respectively (Fig. 1b). 
The Simpson index reflecting community evenness was 
0.023 ± 0.004 and 0.019 ± 0.004 in sham and CKD rats, 
respectively (Fig. 1b). Significant difference was observed 
in β-diversity based on the unweighted (P = 0.005) but not 
t-weighted (P = 0.270) UniFrac between the sham and CKD 
groups (Fig. 1c).
The linear discriminant analysis (LDA) effect size 
(LEfSe, version 1.0) and Wilcoxon rank sum tests were 
used to compare the gut microbiota in the sham and CKD 
rats at different taxonomic levels. CKD altered the struc-
ture and composition of the gut microbiota (Table S1). All 
of the observed sequences could be assigned to 12 phyla. 
Figure 1d demonstrated the difference in the abundant taxa 
between samples from sham and CKD rats using phylum- to 
genus-level data, which indicated the alternation of composi-
tion in the sham and CKD rats. Microbiome in both sham 
and CKD rats were dominated by Firmicutes and Bacteroi-
detes, which are the typical gut microbiome structures in 
rats (Fig. 1e). Firmicutes were the most prominent gut bac-
terial community, accounting for an average of 71.1% and 
65.8% sequences in the sham and CKD rats, respectively. 
Bacteroidetes represented the second dominant gut bacte-
rial community, accounting for an average of 19.9% and 
27.5% sequences in the sham and CKD rats, respectively. 
Other phyla groups including Actinobacteria, Proteobacteria 
and Verrucomicrobia were detected at low levels (less than 
3%) (Fig. 1e). Only the relative abundance of Proteobacte-
ria was significantly increased in CKD rats (2.28% ± 0.01%) 
compared to the sham rats (0.51% ± 0.01%) according to the 
Wilcoxon rank sum test (Fig. 1f). At the class level, Betapro-
teobacteria was obviously increased, while Alphaproteo-
bacteria was evidently decreased in CKD rats (Fig. 1f). In 
addition, enrichments of Enterobacteriaceae, Sutterellaceae 
and Clostridiaceae_1 as well as the depletion of Clostridi-
aceae_2 and Leuconostocaceae were observed in CKD rats 
as well (P < 0.05 or P < 0.01) (Fig. 1f).
Alteration of gut taxa in CKD rats
At the genus level, an average of 72.3% sequences per sam-
ple could not be assigned to specific genera (Fig. 1g), which 
is consistent with the previous report [32]. The remaining 
sequences belonged to 91 genera, among which Lactobacil-
lus, Eubacterium, Allobaculum, Clostridium XlVa, Prevo-
tella, Clostridium IV, Ruminococcus and Romboutsia were 
highly abundant in both groups (Fig. 1g). PICRUSt (ver-
sion 1.1.3) analysis showed that modifications of the gut 
microbiota affected predicted functional metabolic pathways 
(Fig. 1h).
LEfSe analysis showed that the CKD rats were mainly 
characterized by higher abundance of Allobaculum, Escheri-
chia_Shigella, Clostridium_sensu_stricto, Bacteroides, 
Parasutterella, Ruminococcus, Blautia and Enterorhabdus 
(LDA score > 2.0 with P < 0.05), whereas the sham rats pri-
marily showed higher enrichment of Pseudomonas, Alka-
liphilus, Leuconostoc, Lactococcus and Clostridium_IV 
(LDA score > 2.0 with P < 0.05, Fig. 2a, b). Heatmap and 
orthoPLS-DA showed that these taxa could significantly 
separate the CKD rats from the sham rats (Figs. 2c; S1). 
Further, Pearson correlation analysis identified several taxa 
which was strongly correlated with CKD rats (Fig. 2d). To 
Fig. 1  The alteration of gut microbiome in CKD rats. a Physiological 
and biochemical parameters of sham and NX rats. **P < 0.01 versus 
sham rats. b The α-diversity indexes of Chao1, Shannon and Simp-
son of gut microbiota between NX and sham rats. c Principal coor-
dinate analyses based on unweighted and weighted (right) UniFrac 
distances between gut bacterial communities of NX and sham rats. 
P value indicated differential clustering assessed by ADONIS test. 
d The  cladogram of different abundant taxa between samples from 
sham and NX rats using phylum- to genus-level data. e Taxonomic 
distributions of bacteria from colonic lumenal content 16S rDNA 
sequencing data at the phylum level (top 10) between NX and sham 
rats (Wilcoxon rank-sum test). f Comparison of relative abundance of 
significantly altered bacterial taxa including phylum, class and fam-
ily levels between sham and NX rats. The Wilcoxon rank sum test 
was used to determine the  significance between groups. *P < 0.05, 
**P < 0.01 versus sham rats. g Taxonomic distributions of bacte-
ria from colonic lumenal content 16S rDNA sequencing data at the 
genus level (top 30) between NX and sham rats (Wilcoxon rank-sum 
test). h The effect of  the gut microbiota  modifications on predicted 
functional metabolic pathways obtained from PICRUSt analysis of 
16S rRNA sequencing data
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identify correlations between biochemical parameters and 
changes in the gut microbiome in CKD, we performed a 
Spearman correlation analysis of altered 13 gut microbi-
ota and biological parameters. We revealed that CCr and 
SBP were deeply implicated in the alterations of the gut 
microbiome (Fig. 2e). Spearman correlations between CKD-
associated 13 genera as well as nine physiological and bio-
chemical parameters were further observed in a correlation 
network (Fig. 2f). Additionally, we found SBP and CCr 
were the hub of the entire network, with two sub-networks 
produced for physiological parameters and genus (Fig. 2f). 
The findings showed that significant positive correlations 
between increased proteinuria with Blautia and decreased 
hematocrit with Clostridium_IV were independent of CCr. 
Taken together, these results indicated that renal dysfunction 
could influence the structure and composition of gut micro-
biota. In turn, gut microbiota dysbiosis played paramount 
roles in the deterioration of impaired renal function.
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Potential functional impact of CKD‑induced changes 
in the gut microbiome
To predict the possible impact of the altered gut microbi-
ome in CKD rats, OTUs were assigned to the closest refer-
ence genome in the database from the PICRUSt analysis. 
PICRUSt analysis showed that 471 KEGG orthology (KO) 
were associated with 219 altered metabolic pathways, such 
as lipid biosynthesis and metabolism (sphingolipids, fatty 
acids, steroids, bile acids), amino acid biosynthesis and 
metabolism (valine, leucine, isoleucine biosynthesis, phe-
nylalanine, tyrosine, tryptophan and histidine), aminobenzo-
ate degradation, phenylpropanoid biosynthesis and MAPK 
signaling pathway (Table S3), which are associated with 37 
enzymes (Table S4). The metabolic pathways and associ-
ated enzymes were involved in alternation of 33 metabolic 
pathways (Fig. 1h). Gut microbiome was involved in the 
production of the uremic toxins including p-cresyl sulfate 
(PCS) and indoxyl sulfate (IS) which contributed much to 
systemic inflammation, impairment of intestinal barrier 
structure/function, and the progression of CKD [33]. Gut 
microbes can convert phosphatidylcholine and l-carnitine 
into trimethylamine which was metabolized by hepatic fla-
vin monooxygenase to trimethylamine N-oxide (TMAO) 
and finally excreted by the kidney [34]. TMAO was closely 
involved in renal fibrosis as well as CKD progression and its 
complications, such as atherosclerosis and CVD [14]. The 
KO for enzymes were responsible for the production of ure-
mic toxins, such as the tryptophanase, tyrosine phenol-lyase 
gene, and the production of TAMO was searched within the 
closest reference genome of each OTU (Table S2). A total of 
nine OTUs were found to contain the genes encoding tryp-
tophanase (K01667) and/or tyrosine phenol-lyase (K01668) 
in their closest reference genome (Table S2), of which three 
OTUs were assigned to the Proteobacteria phylum (OTUs 
54, 189, and 778) and four OTUs were assigned to the Bac-
teroidetes (OTU 166, 233, 535, and 888) phylum, while 
one OTU was assigned to the Elusimicrobia (OTU 769) 
and Verrucomicrobia (OTU 173) phylums. Genes related to 
the production of trimethylamine (TMA), including K07811 
(trimethylamine oxidoreductase 1), K07821 (trimethylamine 
oxidoreductase 2, c-type cytochrome subtribe activity regu-
lation transducer), and K03532 (trimethylamine oxidoreduc-
tase 1, c-type cytochrome subtribe activity regulation trans-
ducer) were found in closest genome of the following five 
OTUs: Escherichia fergusonii, Aggregatibacter aphrophilus 
NJ8700, Psychrobacter sp. PRwf-1, Desulfovibrio fairfield-
ensis and Helicobacter typhlonius, all of which belonged to 
the Proteobacteria phylum. These species were the candidate 
bacteria producing uremic toxins in the rat’s intestinal tract, 
among which Escherichia fergusonii and Bacteroides the-
taiotaomicron were significantly increased in the CKD rats 
compared to control rats.
Alteration of serum metabolome in CKD rats
UPLC–HDMS was used to identify the metabolite profiles 
in both positive and negative ion modes. We observed higher 
noise and matrix effect resulting in a high baseline in the 
negative ion mode. Therefore, positive ion mode was applied 
for final analysis and 7389 variables were revealed. Score 
plots of OPLS-DA showed that CKD rats could be sepa-
rated from sham rats (Fig. 3a). 1772 variables were selected 
based on S-Plot (Fig. 3b), P < 0.05 (Table S5), adjusted FDR 
(Table S5) and coefficient analyses (Fig. 3c). 291 metabo-
lites were identified based on criteria established in our pre-
viously reported methods [35–37] (Table S5). They could 
differentiate CKD rats from sham rats (Fig. 3d–f) and as 
shown in Fig. 3g, these metabolites were mainly involved 
in fatty acid metabolism (branched chain fatty acid oxida-
tion, linoleic acid, fatty acyl-CoA biosynthesis), amino acid 
metabolism (tryptophan, tyrosine, phenylalanine, histidine, 
lysine, proline, etc.), polyamine metabolism (spermidine and 
spermine biosynthesis) and purine metabolism. Of note, the 
majority of metabolic pathways were associated with the gut 
microbial metabolism, indicating the dysbiosis of gut micro-
biota in CKD rats. Moreover, pathway-associated metabolic 
networks indicated that dysregulations of the metabolic 
pathways were also related to the metabolism of methyl-
histidine, phenylalanine, tyrosine, glycine, serine, trypto-
phan and butyrate as well as the biosynthesis of spermidine, 
spermine, phospholipid and fatty acid (Figs. S2A, S2B, S3 
and Table S6). Taken together, CKD was closely associated 
with altered amino acid, polyamine and lipid metabolisms.
Fig. 2  Significantly altered bacterial taxa in CKD rats. a LDA score 
of the significantly discriminant genera between the two groups (LDA 
score > 2.0, Wilcoxon rank-sum tests, P < 0.05). b Boxplots showing 
differences in the relative abundance of 13 significantly discriminant 
taxa driving gut microbiome differences between NX and sham rats. 
*P < 0.05, **P < 0.01 versus sham rats (n = 6). c orthoPLS-DA plots 
with the scores of the first two principal components based on 13 
taxa from the NX and sham rats. d Correlations of 13 significantly 
discriminant taxa in NX and sham rats using Spearman correlation 
analysis. Asterisks denoted statistical significance between bacterial 
taxa, *P < 0.05, #P < 0.01. e Spearman’s rank correlation between 
13 most differential genera selected from the LEfSe and clinical 
biochemical parameters. The results were presented as a heatmap 
using Ward clustering analysis. Heatmap showed that microbial taxa 
was  intimately  associated with metabolites, which was positively or 
negatively related  to clinical chemistry. Rho in the color key repre-
sented Spearman rank correlation coefficient. *P < 0.05, #P < 0.01 
denoted statistical significance between bacterial taxa and biochemi-
cal parameters. f The construction of correlation network by using the 
perfuse force directed layout in the Cytoscape software. The nodes 
of the network represented the genera and clinical indices, where the 
edges corresponded to a significant (P < 0.05) and positive (blue) or 
negative (yellow) correlation between the nodes. The border width of 
the nodes and edges (connections) represented relative abundance of 
clinical parameters and bacterial taxa
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Association of the CKD‑induced gut microbial 
dysbiosis with dysregulation metabolites
To further investigate the potential role of the altered gut 
microbiota in the pathogenesis of altered metabolites, we 
performed a Spearman correlation analysis. As shown in 
Fig. 4a, 36 metabolites were significantly associated with 13 
altered microbial genera. Decreased tyrosine and tryptophan 
showed a positive correlation with Clostridium_IV and a 
negative correlation with Allobaculum, Clostridium_sensu_
stricto, Escherichia_Shigella, Enterorhabdus and Blautia. 
Most of metabolites such as TMAO, glycine, cinnamoylg-
lycine, phenylacetylglycine, phenylpropionylglycine, sper-
mine, spermidine, acrolein, putrescine and N1-acetylsper-
midine were obviously increased in CKD rats and showed 
a positive correlation with Clostridium_sensu_stricto, 
Fig. 3  Metabolic profile as well as multivariate analysis and meta-
bolic pathway of metabolites in NX rats. a OPLS-DA plots with the 
scores of the first two principal components. b S-plots of OPLS-DA 
model from the NX and sham rats. c Loading plots of OPLS-DA 
model from the NX and sham rats. d Dendrogram analysis based on 
291 metabolites. e Heatmap analysis of 291 metabolites. f PCA plots 
with the scores of the first two principal components based on 291 
metabolites. g Metabolite pathway analysis of 291 metabolites by 
MetScape software running on cytoscape based on KEGG, Reactome 
and SMPDB database. The border width of the nodes and edges (con-
nections) represented relative abundance of clinical parameters and 
bacterial taxa
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Escherichia_Shigella, Enterorhabdus, Parasutterella and 
Blautia that harbored genes encoding enzymes involved in 
glycine-conjugated metabolites and polyamine metabolism.
Spearman correlation analysis was performed using SBP 
and 36 metabolites. Figure 4b presented the relative inten-
sities determined by metabolomic method and P values 
(< 0.05) were calculated by Spearman correlation analysis 
based on the values of SBP and relative intensities of 16 
metabolites. The Spearman correlation analysis revealed 
that SBP was associated with 16 metabolites. Interestingly, 
ten compounds, such as cinnamoylglycine, 2-phenylacetic 
acid, phenylacetylglycine, phenylpropionylglycine and 
hippuric acid, were glycine-conjugated microbial metabo-
lites (Fig. 4c). For example, hippuric acid was produced 
by the conjugation of benzoic acid with glycine, a reaction 
that occurred in the liver, kidney and intestine. The glycine 
could directly conjugate to phenylpropionic acid, a known 
metabolic byproduct of anaerobic bacteria. However, phe-
nylpropionic acid was normally converted to benzoic acid 
by β-oxidizing medium-chain acyl-CoA dehydrogenase in 
humans. These findings demonstrated that glycine bioac-
tivity was partly associated with CKD-induced hyperten-
sion. Increased glycine-conjugated metabolites including 
cinnamoylglycine, phenylpropionylglycine, 2-phenylacetic 
acid and hippuric acid showed strong positive correlations 
with Escherichia_Shigella, Enterorhabdus, Parasutterella 
and Bacteroides, as well as strong negative correlation with 
Clostridium_IV, which possessed genes encoding glycine 
dehydrogenase (K00281), glycine oxidase (K03153), glycine 
reductase (K10670) and 3-phenylpropionate/cinnamic acid 
dioxygenase subunit α (K05708) as well as their correspond-
ing enzymes (EC:1.4.4.2), (EC:1.4.3.19), (EC:1.21.4.2) and 
(EC:1.14.12.19) that converted spermine or spermidine to 
other polyamines (Fig. 4b).
Increased spermine, spermidine, acrolein, N1-acetyl-
spermidine and N1,N12-diacetylspermine in CKD rats 
were mainly implicated in the enrichments of Clostridium_
sensu_stricto, Escherichia_Shigella, Enterorhabdus and 
Parasutterella, which possessed genes encoding spermine 
synthase (K00802), spermidine synthase (K00797), sper-
midine dehydrogenase (K00316), homospermidine synthase 
(K00808) and putative spermidine/putrescine transport sys-
tem permease protein (K02053) as well as their correspond-
ing enzymes (EC:2.5.1.22), (EC:2.5.1.16), (EC:1.5.99.6) 
and (EC:2.5.1.44) that converted spermine or spermidine 
to other polyamines (Fig. 5b). However, increased putres-
cine was only associated with Bacteroides, which possessed 
genes encoding putrescine aminotransferase (K09251, 
K12256), spermidine/putrescine transport system permease 
protein (K11070, K11071) and putrescine carbamoyltrans-
ferase (K13252) as well as their corresponding enzymes 
(EC:2.6.1.82), (EC:2.6.1.-) and (EC:2.1.3.6) that converted 
spermidine to putrescine (Fig. 5b).
Metabolic network modeling and microbiome–
metabolite associations in gut microbiota–
metabolite–phenotype axis
To assess the potential role of the altered metabolites with 
renal function, we performed a Spearman correlation and 
linear regression analyses of CCr and metabolites using 
gut microbiota-associated 36 metabolites. 15 metabolites 
showed a significant correlation with CCr and had linear 
regression coefficient of more than 0.800 (Fig. 5a). Of note, 
these metabolites belonged to polyamine metabolism (sper-
mine, spermidine, acrolein, putrescine, 3-aminopropanal, 
N1-acetylspermidine and N1,N12-diacetylspermine). Poly-
amines have been identified as uremic toxins, which acceler-
ate progression of renal fibrosis [38]. Figure 5b presented the 
polyamine metabolism pathway in CKD rats.
The influence of gut microbiota on the host’s metabolic 
activity has been studied widely, which contributes much 
on both local and systemic metabolism. To further explore 
the association among clinical indices, bacterial genus and 
metabolites, a network analysis based on nine clinical indi-
ces, 13 genus-level bacterial taxa, seven metabolites in gly-
cine metabolic pathway and six metabolites in polyamine 
metabolism was used to highlight the associations of the 
gut microbiome with clinical indices and serum metabolites 
in renal fibrosis by Cytoscape software (version 3.6.1). As 
shown in Fig. 5c, CCr was directly linked to dysbiosis of gut 
microbiota, clinical indices and metabolites, which indicated 
that the renal function decline was associated with microbial 
composition, glycine metabolism and polyamine metabolism 
that contributed to renal fibrosis. Gut microbiota was deeply 
implicated in glycine metabolism and polyamine metabo-
lism. Interestingly, hypertension exhibited a higher positive 
correlation with the dysregulation of glycine metabolism and 
microbiome; however, CCr had a higher negative correlation 
with upregulated polyamine metabolism and microbiome in 
NX rats, underscoring the connection between strong vari-
ations in microbial abundance and metabolic regulation in 
NX rats.
Effects of PAA and Poria cocos (PC) administration 
on gut microbiome, serum metabolites and renal 
fibrosis in CKD rats
To demonstrate whether gut microbiome could affect renal 
fibrosis, CKD rats were treated with PC, a well-known 
natural fungus with marked antioxidative, antiinflamma-
tory, antibacterial, diuretic and antifibrotic effects on CKD 
[39–45]. PAA is a major tetracyclic triterpenoid derivative 
of PC [46–48]. As shown in Fig. 6a, b, treatment with both 
PAA and PC improved glycine and polyamine metabo-
lisms in CKD rats. Interestingly, PAA treatment showed a 
stronger effect on glycine metabolism than that of PC., while 
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PC treatment was relatively more prominent on polyamine 
metabolism compared to PAA. In addition, emerging evi-
dence suggested that altered gut microbiota was, in part, 
responsible for the pathogenesis of hypertension, accumu-
lation of uremic toxin and the decline in kidney function 
[8, 9, 49]. It was speculated that PAA improved renal func-
tion and attenuated interstitial fibrosis partly by lowering 
blood pressure. However, PC improved renal function and 
reduced fibrosis partly by lessening the generation of pol-
yamine-derived uremic toxins. Present study showed that 
treatment with both PAA and PC could attenuate CKD and 
its consequences (Fig. 6c). Notably, PAA treatment showed 
a stronger effect on improving renal function than PC, which 
indicated the contribution of hypertension on CKD progres-
sion. Moreover, both PAA and PC treatment can upregu-
late the protein expression of ZO1, occludin and claudin-1 
(Fig. 6d, e).
The breakdown of the gut epithelial barrier triggered 
local and systemic inflammation and influx of leukocytes as 
well as accelerated the translocation of uremic toxins into 
the systemic circulation in CKD patients and animals [8]. 
NX rats exhibited a significant upregulation in nuclear trans-
location of p65, pointing to the activation of NF-κB signal-
ing (Fig. 7a). Activation of IκBα/NF-κB was accompanied 
by marked upregulation of inflammatory proteins including 
MCP-1 and COX-2, as well as the downregulation of anti-
oxidative system including Nrf2 and its downstream gene 
products, such as HO-1, catalase and NQO1 (Fig. 7a–d). 
Both PAA and PC treatment inhibited the upregulation of 
IκB/NF-κB pathway and prevented the downregulation of 
cytoprotective Keap1/Nrf2 pathway. Interestingly, PAA 
showed a stronger effect on these pathways than that of PC 
(Fig. 7a–d).
Oxidative stress and inflammation played paramount roles 
in the pathogenesis and progression of CKD [29, 50, 51]. 
Compared to sham rats, the CKD rats showed interstitial 
inflammatory cell infiltration and tubular atrophy/dilatation 
(Fig. 7e). Histological analysis indicated that both PAA and 
PC treatment significantly attenuated renal injury (Fig. 7f). 
Immunohistochemical staining showed that treatment with 
both PAA and PC inhibited the upregulation of profibrotic 
factors including α-SMA, vimentin and collagen I (Fig. 7e). 
Interestingly, PAA showed a stronger antifibrotic effect than 
that of PC. Taken together, these results suggest that PAA 
and PC treatment could ameliorate inflammation and oxida-
tive stress as well as retard renal fibrosis in the CKD rats by 
attenuating microbial dysbiosis, preventing disruption of 
intestinal epithelial barrier, and mitigating dysregulation of 
serum metabolites.
Discussion
The present study demonstrated profound changes of the 
gut microbiome marked by altered composition and reduced 
diversity of the bacterial population in CKD rats, which was 
highly consistent with the earlier studies [9]. In confirma-
tion of the previous studies, microbial dysbiosis in CKD rats 
was accompanied by marked alteration of plasma metabo-
lome [52]. The microbial-derived metabolites were closely 
linked to the inflammation and oxidative stress in CKD rats. 
A growing body of evidence demonstrated that dietary sup-
plementation of amylose, a plant-derived indigestible com-
plex carbohydrate, ameliorated oxidative stress as well as 
inflammation and retarded the progression of chronic kidney 
disease in CKD rats [53]. Additionally, amylose improved 
microbial dysbiosis and metabolomic profiles [52] in rats 
with adenine-induced chronic interstitial nephropathy as 
well. Present study reveals that dietary supplementation 
of the prebiotics, PC and PAA could ameliorate microbial 
dysbiosis, lower the related toxic metabolites, mitigate 
interstitial fibrosis and retard the decline of renal function 
in rats with CKD induced by 5/6 nephrectomy. Significant 
changes in the abundance of 13 bacterial species including 
Blautia, Escherichia_Shigella, Bacteroides, Allobaculum 
and Clostridium_IV, and 291 metabolites were observed in 
CKD rats, highlighting the critical impact of CKD on the gut 
microbiome and its role in dysregulated metabolites.
Dysbiosis of the gut microbiota has been described pre-
viously in CKD rats and humans [9, 32]. Using phylogenic 
microarray technique, in a previous study we compared the 
composition of the bacterial community in fecal samples 
of rats with CKD induced by 5/6 nephrectomy with that 
of sham-operated control rats. The study revealed reduced 
richness and distinct changes in composition of bacterial 
community structure in CKD rats [9]. In a subsequent study, 
Fig. 4  Correlation analysis of the gut microbiome and serum metabo-
lites as well as relationship between hypertension and serum metabo-
lites. a Spearman’s rank correlation between 13 most differential gen-
era and 36 differential metabolites (metabolite that correlated with at 
least one genus with P < 0.05 was shown). The results were presented 
as a heatmap using Ward clustering analysis. The scale ranged from 
+ 2.0 (red) to − 2.0 (green). Heatmap showed that microbial taxa was 
correlated with metabolites, which  linked positively or negatively 
to renal fibrosis in NX rats. Rho in the color key represented Spear-
man rank correlation coefficient. *P < 0.05, #P < 0.01 denoted statis-
tical significance between bacterial taxa and metabolites. b Relative 
intensity of individual metabolites in NX and sham rats. 16 metabo-
lites were selected by correlation analysis between metabolites and 
SBP (P < 0.05). P value was calculated by Spearman rank correla-
tion. Vertical axis was the relative intensity of individual metabolites. 
Asterisks denoted statistical significance between NX and sham rats, 
**P < 0.01 versus the relative intensity of the sham rats. c Analysis 
of the metabolites in glycine pathway. The relative intensities in the 
serum metabolites were shown in boxes. Metabolites highlighted by 
red indicated the identified metabolites and their relative intensities 
were presented in b in current study
◂
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Kikuchi et al. [32] found reduced diversity and altered com-
position of the gut microbial community in the fecal sam-
ples of NX rats compared to those of sham-operated con-
trol rats. In confirmation of the above studies, Firmicutes, 
Bacteroidetes, Proteobacteria and Actinobacteria were the 
most dominant bacterial phylum in the colon content from 
our rats. As expected, the CKD rats showed significant alter-
nation of the gut microbiome. In particular, at the genus 
level, we found the enrichment of Enterorhabdus, Blautia, 
Ruminococcus, Parasutterella, Bacteroides, Clostridium_
sensu_stricto, Escherichia_Shigella and Allobaculum, and 
the depletion of Clostridium_IV, Lactococcus, Leuconostoc, 
Alkaliphilus and Pseudomonas in our CKD rats. These find-
ings confirmed the concurrence of gut microbial dysbiosis 
in CKD. One of the striking changes of the microbiome in 
CKD rats employed in the present study and in CKD rats 
and ESRD patients in previous studies [32, 54] is enrich-
ment of Escherichia_Shigella which consists of one of the 
species assigned to Escherichia fergusonii. E. fergusonii is 
an enterotoxin-producing bacterium responsible for a wide 
variety of intestinal and extra-intestinal infections in animals 
and humans [55, 56]. Enrichment of the E. fergusonii, an 
aerobic bacterium in our CKD rats, is consistent with the 
Fig. 5  Associations of the gut microbiome with clinical indices and 
serum metabolites in renal fibrosis. a The associations between CCr 
and taxa-associated significant metabolites in NX rats. r indicated the 
linear coefficients. Metabolites were selected based on R > 0.800. The 
values of P were calculated by Spearman rank correlation between 
CCr and metabolites. b Analysis of the metabolites of the spermine 
pathway. The relative intensities in the serum metabolites were shown 
in boxes. Metabolites highlighted by red  indicated the identified 
metabolites in current study. c Correlation network among 13 genus-
level bacterial taxa, nine clinical indices and seven metabolites in gly-
cine metabolic pathway and six metabolites in polyamine metabolism 
by Cytoscape software. The nodes of the network represented the 
genera (yellow circle), clinical indices (green hexagon) and glycine 
metabolites (blue rectangle) as well as polyamine metabolites (pink 
octagon), where the edges corresponded to a significant (P < 0.05) 
and positive (Spearman rho < − 0.3) or negative (Spearman rho > 0.3) 
correlation between the nodes
◂
Fig. 6  Effects of PAA and PC on serum metabolites, clinical indices 
and intestinal barrier in NX rats. a Relative intensity of individual 
glycine metabolites in the serum of the different rats. Vertical axis 
was the relative intensity of individual metabolites. b Relative inten-
sity of individual polyamine metabolites in the serum of the different 
rats. Vertical axis was the relative intensity of individual metabolites. 
c Clinical indices of the different rats. d The expression levels of the 
tight junction protein expressions including ZO1, occludin and clau-
din-1 in the colon of the different rats. Tissue lysates were immunob-
lotted with specific antibodies against ZO1, occludin and claudin-1. e 
Graphic representations of ZO1, occludin and claudin-1 expression in 
different groups as indicated. *P < 0.05; **P < 0.01 versus sham rats 
(n = 6); #P < 0.05, ##P < 0.01 versus NX rats (n = 6)
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previously demonstrated expansion of aerobic bacteria in 
the hemodialysis patients [57]. In addition, E. fergusonii’s 
genome contains genes encoding enzymes capable of pro-
ducing the gut-derived uremic toxins IS, p-CS and TMAO, 
pointing to the potential effect of E. fergusonii on uremic 
toxin production in the rats’ intestine.
The Blautia population was markedly elevated in our 
CKD rats, which provided additional evidence to the earlier 
study reported by Zeng et al. [58]. In addition, the rise in 
Blautia has been shown to be associated with early decline 
in renal function (eGFR decline) in a large cohort of patients 
with minimal renal dysfunction [59]. Vancomycin admin-
istration in ESRD patients has been shown to significantly 
reduce Blautia, and lower serum IS and p-CS levels at day 7 
followed by their rebound to or above baseline values at day 
28 [60]. IS and PCS are the byproducts of tryptophan and 
tyrosine metabolism by the gut bacteria and their rise within 
28 days following vancomycin therapy in ESRD patients 
points the resilience of the taxa generating these toxins [60].
Increased abundance of Ruminococcus and Allobaculum 
genera observed in our CKD rats is consistent with the previ-
ously reported findings in mice with adenine-induced CKD and 
rats with 5/6 nephrectomy-induced CKD [32, 58, 61]. Moreo-
ver, consumption of high-fiber diets has been shown to obvi-
ously reduce the abundance of Ruminococcus and Allobacu-
lum in rats with adenine-induced CKD [52]. Moreover, other 
study showed that Ruminococcus was positively correlated with 
eGFR decline in CKD patients [62]. The increased abundance 
of the fragments of Bacteroides genera has been reported in the 
blood samples of ESRD patients [63] and patients with kidney 
stone [64]. Interestingly, the alternation of Blautia, Bacteroides, 
Escherichia_Shigella and Allobaculum has been reported in 
rats with spontaneous hypertension [65], coinciding with our 
findings in CKD rats which had hypertension. Our CKD rats 
had increased abundance of Parasutterella.
In our CKD rats, we found depletion of Clostridium IV 
bacteria which produced short-chain fatty acid (SCFA), 
especially butyrate that had antiinflammatory and protec-
tive effects on the colonic epithelium [66]. Most of the 
Clostridium IV OTUs could not be identified as specific spe-
cies, indicating that unknown Clostridium spp. was involved 
in the maintenance of gut bacterial homeostasis. Colonic 
colonization of Clostridium spp. was related to accumula-
tion of Treg lymphocytes which inhibited the development 
of inflammatory lesions [67]. Two Clostridium IV species 
including Clostridium leptum and Eubacterium siraeum 
were significantly decreased in our CKD rats. C. leptum can 
induce stimulation of Treg cells and inhibit the inflammatory 
response [68]. The observed depletion of the antiinflamma-
tory bacteria may contribute to the inflammatory state in 
CKD rats. Pseudomonas genus was evidently decreased in 
our CKD rats, which was consistent with previous studies 
in ESRD patients [69]. The enrichment of Lactococcus and 
Leuconostoc were observed in our study as well. Tain et al. 
[70] reported the association of increased Lactococcus and 
decreased Leuconostoc with the development of hyperten-
sion by maternal and post-weaning high-fructose diets in 
adult offspring.
Dysbiosis of the gut microbiota in our CKD rats was 
accompanied by the alteration of serum metabolome. Cor-
relation analysis demonstrated that increased spermine, 
spermidine, acrolein, N1-acetylspermidine and N1,N12-
diacetylspermine were mainly associated with the enrich-
ment of microbial genera which possess the genes encoding 
spermine synthase, spermidine synthase, spermidine dehy-
drogenase and homospermidine synthase, putative sper-
midine/putrescine transport system permease protein and 
their corresponding enzymes (EC:2.5.1.22), (EC:2.5.1.16), 
(EC:1.5.99.6) and (EC:2.5.1.44) that convert spermine or 
spermidine to other polyamines. However, increased putres-
cine was only associated with Bacteroides which possesses 
genes encoding putrescine aminotransferase and putres-
cine carbamoyl transferase as well as their corresponding 
enzymes [(EC:2.6.1.82), (EC:2.6.1.-) and (EC:2.1.3.6)] that 
convert spermidine to putrescine. Polyamines are among the 
uremic toxins which accelerate progression of uremia [71, 
72]. Polyamines originate from l-ornithine and methionine 
by ornithine decarboxylase (EC 4.1.1.17). Decarboxylation 
of l-ornithine leads to the production of putrescine which is 
further converted to higher polyamines spermidine and sper-
mine by successive addition of aminopropyl groups derived 
from decarboxylated S-adenosylmethionine. These metab-
olites which are linked with CCr correlated with specific 
gut microbiota. Microbiota-derived polyamine metabolites 
exacerbate the damage of intestinal epithelial tight junction, 
which in turn accelerates the translocation of uremic toxins 
into the systemic circulation and promotes local and sys-
temic inflammations [8].
Fig. 7  Effects of PAA and PC on inflammation and TIF in NX rats. 
a Western blot depicting IκBα, p-IκBα and nuclear content of p65 
active subunit of NF-κB and expression of COX-2 and MCP-1 in 
kidney tissues of different rats. Tissue lysates were immunoblotted 
with specific antibodies against IκBα, p-IκBα, NF-κB, COX-2 and 
MCP-1. b Graphic representations of IκBα, p-IκBα, NF-κB, COX-2 
and MCP-1 expression in different groups. c Western blot depicting 
nuclear translocation of Nrf2 and protein abundances of its repressor, 
Keap1, and its downstream gene products, such as catalase, HO-1 and 
NQO-1 expression in kidney tissues of different rats. Tissue lysates 
were immunoblotted with specific antibodies against Keap1, Nrf2, 
catalase, HO-1 and NQO-1. d Graphic representations of Keap1, 
Nrf2, catalase, HO-1 and NQO-1 expression in different groups. e 
Images of PAS staining, Masson’s Trichrome staining and immuno-
histochemical staining of α-SMA, vimintin and collagen I expression 
in different rats. f Graphic representations of PAS staining includ-
ing tubulointerstitial damage, glomerulosclerosis score, Masson’s 
Trichrome staining and immunohistochemical staining in different 
groups. *P < 0.05; **P < 0.01 versus sham rats (n = 6); #P < 0.05, 
##P < 0.01 versus NX rats (n = 6)
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Treatment of PAA and PC in CKD rats prevented the dis-
ruption of intestinal epithelial barrier by downregulating pol-
yamine metabolites as well as upregulating ZO1, occludin 
and claudin-1 protein expression. In addition, it mitigated 
inflammation and oxidative stress by inhibiting IκBα/NF-κB 
pathway and maintaining Keap1/Nrf2 pathway as well, the 
dysregulation of which contributed much to renal fibrosis 
in the untreated CKD rats. Finally, PAA and PC treatment 
also improved CCr as well as lowered SBP, DBP, serum cre-
atinine, urea concentrations, proteinuria, and downregulated 
α-SMA, vimentin and collagen I expression in CKD rats.
Our study further indicated that the elevated blood pres-
sure was deeply implicated in glycine metabolism pathway. 
Glycine-conjugated metabolites including cinnamoylglycine, 
phenylpropionylglycine, 2-phenylacetic acid and hippuric 
acid showed strong positive or negative correlation with 
five genera in CKD rats. Although both the treatment of 
PAA and PC could alter metabolites derived from glycine 
and polyamine metabolism, PAA exhibited a stronger effect 
on lowering production of glycine-conjugated metabolites 
as well as the downregulation of α-SMA, vimentin and 
collagen I expressions in CKD rats. Taken together, these 
microbial genera and glycine-conjugated metabolites were 
intimately involved in renal injury and hypertension.
Conclusion
CKD significantly modified the structure and composition 
of gut bacteria in rats. The shifts in the composition of the 
gut bacteria, in turn, played an important role in the pro-
gression of CKD. In this study, we demonstrated the CKD-
induced microbial dysbiosis and the dysregulation of micro-
bial metabolites as well as their impact on renal fibrosis and 
renal impairment. Additionally, we further showed that 
treatment with PAA and PC mitigated microbial dysbiosis, 
attenuated oxidative stress, inflammation and renal fibrosis, 
and retarded the decline of renal function in rats with CKD 
induced by 5/6 nephrectomy.
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